Setsuo Funasaka
Koishikawa, 1128088, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.
Journal: Japanese journal of clinical oncology
Published: March 10, 2025
Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: May 21, 2024
Effects of Food, Gastric Acid Reduction, and Strong CYP3A Induction on the Pharmacokinetics of Tasurgratinib, a Novel Selective Fibroblast Growth Factor Receptor Inhibitor.
Journal: Journal of clinical pharmacology
Published: April 03, 2024
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 06, 2018
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Journal: Molecular cancer therapeutics
Published: May 06, 2016
Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: June 02, 2014
Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor.
Journal: International journal of molecular medicine
Published: October 19, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026